Meeting
2022 ASCO Annual Meeting
Combination of nivolumab with chemoradiotherapy for locally advanced cervical cancer: NiCOL phase I trial.
Authors
Manuel Rodrigues
Medical Oncology, Institut Curie, Paris, France
Manuel Rodrigues , Pierre Loap , Coraline Dubot , Catherine Durdux , Louis Bazire , Mathieu Minsat , Virginie Fourchotte , Enora Laas , Marion Chevrier , Emanuela Romano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT03298893
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5534)
DOI
10.1200/JCO.2022.40.16_suppl.5534
Abstract #
5534
Poster Bd #
413
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.
First Author: Manabu Muto
Poster
2017 ASCO Annual Meeting
A phase I study of sequential ipilimumab in the definitive treatment of node positive cervical cancer: GOG 9929.
First Author: Jyoti Mayadev
Poster
2024 ASCO Gastrointestinal Cancers Symposium
FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)—Primary safety and short-term efficacy results for cohort E.
First Author: Takako Yoshii
Poster
2022 ASCO Gastrointestinal Cancers Symposium
FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)—Short-term results for cohorts C and D.
First Author: Satoru Matsuda